You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,625,755


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,625,755
Title:Conditional knockout method for gene trapping and gene targeting using an inducible gene silencer
Abstract: A method for conditionally knocking out and altering gene function and genetic sequences that can be used in such methods, for use in gene trapping and gene targeting. Specifically, the genetic sequence is a inducible gene silencer comprising: (a) a splice acceptor sequence; (b) an internal ribosomal entry site (IRES) sequence; (c) a nucleotide sequence coding for a reporter protein; (d) a polyadenylation sequence; and (e) a pair of oppositely oriented recombination site sequences, which cause single cycle inversions in the presence of a suitable recombinase enzyme, flanking elements (a) through (d).
Inventor(s): Askew; G. Roger (Boxford, MA), Kanki; Kim L. (Boxford, MA)
Assignee: Wyeth (Madison, NJ)
Application Number:10/448,395
Patent Claims:1. An inducible gene silencer set forth in SEQ ID NO:1.

2. A vector comprising the inducible gene silencer set forth in claim 1 in an active orientation.

3. A vector comprising the inducible gene silencer set forth in claim 1 in an inert orientation.

4. An isolated embryonic stem (ES) cell comprising the vector of claim 2.

5. An isolated embryonic stem (ES) cell comprising the vector of claim 3.

6. A conditional knockout gene trapping or gene targeting method comprising the steps of: (a) inserting the inducible gene silencer of claim 1 into a vector in an inert orientation; (b) transfecting the vector comprising the inducible gene silencer into a host cell; (c) delivering a suitable recombinase enzyme, or a polynueleotide encoding a suitable recombinase enzyme, to the transfected host cell in vitro, at any desired time, to cause the inducible gene silencer to invert into an active orientation, such that the inducible gene silencer knocks out the functioning of a gene into which it has inserted, and expresses a reporter protein.

7. The method of claim 6, wherein the suitable recombinase enzyme in step (c) is Cre recombinase.

8. The method of claim 6, wherein the host cell is an ES cell.

9. A method of knocking out the expression of a gene of interest at a future point in time, comprising the steps of: (a) inserting the inducible gene silencer of claim 1 into an intron of the gene of interest in an inert orientation; and (b) exposing the gene of interest containing the inducible gene silencer to a recombinase enzyme in vitro at the future point in time, such that the inducible gene silencer inverts to an active orientation, thereby causing the gene of interest to cease normal expression.

10. The method of claim 9, wherein the recombinase enzyme in step (b) is Cre recombinase.

11. A eukaryotic gene comprising, within its introns, a first inducible gene silencer, according to SEQ ID NO: 1 set forth in claim 1, in combination with one or more exogenous elements selected from the group consisting of: (a) a second inducible gene silencer comprising either a splice acceptor and a selection marker or a splice acceptor and a reporter protein, flanked by Frt sites; (b) a Lox site containing a core mutation; and (c) a pair of Lox sites, each placed in the same orientation within different introns, such that the pair of Lox sites flanks one or more exons.

12. An inducible gene silencer comprising the sequence set forth from nucleotides 120 to 2050 of SEQ ID NO:1.

13. A conditional knockout gene trapping or gene targeting method comprising the steps of: (a) inserting the inducible gene silencer of claim 1 into a vector in an inert orientation; (b) transfecting the vector comprising the inducible gene silencer into a host cell, wherein the host cell is a mouse ES cell; (c) delivering a suitable recombinase enzyme, or a polynucleotide encoding a suitable recombinase enzyme, to a mouse developed from the host cell, at any desired time, to cause the inducible gene silencer to invert into an active orientation, such that the inducible gene silencer knocks out the ftinctioning of a gene into which it has inserted, and expresses a reporter protein.

14. The method of claim 13, wherein the suitable recombinase enzyme in step (c) is Cre recombinase.

15. A method of knocking out the expression of a gene of interest at a future point in time, comprising the steps of: (a) inserting the inducible gene silencer of claim 1 into an intron of the gene of interest in an inert orientation; (b) transfecting a vector containing the gene of interest comprising the inducible gene silencer into a mouse ES cell; and (c) exposing the gene of interest in a mouse developed from the ES cell to a recombinase enzyme at the future point in time, such that the inducible gene silencer inverts to an active orientation, thereby causing the gene of interest to cease normal expression.

16. The method of claim 15, wherein the recombinase enzyme in step (c) is Cre recombinase.

Details for Patent 7,625,755

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.